{
    "organizations": [],
    "uuid": "5ecc00079c39931c09b1da2c87fff40836cc068d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tesaro-and-medison-enter-into-excl/brief-tesaro-and-medison-enter-into-exclusive-distribution-agreement-to-commercialize-zejula-in-israel-idUSFWN1RO0PU",
    "ord_in_thread": 0,
    "title": "BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - TESARO Inc:\n* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULAÂ® IN ISRAEL\n* FURTHER TERMS OF AGREEMENT WERE NOT DISCLOSED * MEDISON WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE ZEJULA IN ALL INDICATIONS, EXCLUDING PROSTATE CANCER, IN ISRAEL\n* MEDISON TO ALSO BE RESPONSIBLE FOR ANY POTENTIAL PATIENT ACCESS PROGRAMS PRIOR TO REGULATORY APPROVAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-11T20:47:00.000+03:00",
    "crawled": "2018-04-12T14:09:07.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "tesaro",
        "inc",
        "tesaro",
        "medison",
        "enter",
        "exclusive",
        "distribution",
        "agreement",
        "commercialize",
        "israel",
        "term",
        "agreement",
        "disclosed",
        "medison",
        "exclusive",
        "right",
        "commercialize",
        "zejula",
        "indication",
        "excluding",
        "prostate",
        "cancer",
        "israel",
        "medison",
        "also",
        "responsible",
        "potential",
        "patient",
        "access",
        "program",
        "prior",
        "regulatory",
        "approval",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}